Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.62 |
| ▸ | RXRB | P28702 | 7/20 | 0.56 |
| ▸ | RXRG | P48443 | 7/20 | 0.56 |
| ▸ | RARA | P10276 | 5/20 | 0.56 |
| ▸ | RARB | P10826 | 5/20 | 0.56 |
| ▸ | RARG | P13631 | 5/20 | 0.56 |
| ▸ | HNF4A | P41235 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8704549 | 0.86 | RXRA (0.71) | RXRARXRBRXRGRARARARB | |
| SCHEMBL13668258 | 0.85 | RXRA (0.48) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6909578 | 0.83 | RXRA (0.64) | RXRARXRBRXRGRARARARB | |
| SCHEMBL12418596 | 0.83 | RXRA (0.50) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6834543 | 0.82 | RXRA (0.58) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6275679 | 0.82 | RXRA (0.47) | RXRARXRBRXRGRARARARB | |
| SCHEMBL727284 | 0.81 | RXRA (0.60) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6916157 | 0.80 | RXRA (0.47) | RXRAHNF4A | |
| SCHEMBL6910700 | 0.80 | RXRA (0.47) | RXRARXRBRXRGRARARARB | |
| SCHEMBL15348324 | 0.79 | RXRA (0.51) | RXRARXRBRXRGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2345409-A1 | THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA | Kagoshima University (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1704139-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RAR y RETINOID RECEPTORS | Allergan, Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1587779-A1 | 5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL 2,6-DIFLUOROHEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | Allergan, Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6759547-B1 | REDUCES SERUM GLUCOSE AND SERUM TRIGLYCERIDE LEVELS IN DIABETIC MAMMALS WITHOUT THE UNDESIRABLE PROPERTIES OF REDUCING SERUM THYROXINE LEVELS AND TRANSIENTLY RAISING TRIGLYCERIDE LEVELS | ALLERGAN, INC. | 2004-07-06 | — | — | US | disclosed |
| US-5055622-A | For treating neoplasms and dermatoses | HOFFMANN-LA ROCHE INC. (US) | 1991-10-08 | — | — | US | disclosed |
| US-5030765-A | Skin disorders, anititumor agents | HOFFMANN-LA ROCHE INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-5030764-A | Antitumor agents; treatment of skin disorders | HOFFMANN-LA ROCHE INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-5001276-A | Novel tetrahydronaphthalene and indane derivatives | HOFFMANN-LA ROCHE INC. (US) | 1991-03-19 | — | — | US | disclosed |
| US-4990703-A | Novel tetrahydronaphthalene and indane derivatives | HOFFMANN-LA ROCHE INC. (US) | 1991-02-05 | — | — | US | disclosed |
| US-4935560-A | ANTITUMOR AGENTS; SKIN DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-06-19 | — | — | US | disclosed |
| US-4870219-A | NEOPLASMS, DERMATOSES | HOFFMANN-LA ROCHE INC. (US) | 1989-09-26 | — | — | US | disclosed |
| US-4326055-A | ANTITUMOR AGENTS, SKIN DISORDERS, RHEUMATIC DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1982-04-20 | — | — | US | disclosed |
| EP-0002742-A1 | Stilbene derivatives, their preparation and medicines containing these stilbene derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | CBR3, CD47, ATL3 | RXRA 1135/4885RXRB 1301/4885RXRG 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.